West Tower Group’s Neurocrine Biosciences NBIX Stock Holding History

West Tower Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-114	Closed	-$15K	–	367
2023 Q4	$15K	Buy	+114	New	+$13.1K	0.03%	315

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

West Tower Group's NBIX Position: Q1 2024 in Review

West Tower Group sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 114 shares — an estimated $15K sold.

West Tower Group first reported a position in NBIX in Q4 2023 and held it in 1 quarter. The position peaked at $15K in Q4 2023. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

West Tower Group reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
West Tower Group sold 114 Neurocrine Biosciences shares in Q1 2024, an estimated $15K.
West Tower Group first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 1 quarter.
West Tower Group's Neurocrine Biosciences position peaked at $15K in Q4 2023.
589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on West Tower Group's 13F filing for Q1 2024, filed 14 May 2024.